R&D COLLABORATIVE PROPOSAL / COMPANY PARTNER SEARCH

The information you are about to provide in this form will be distributed among Chinese companies matching your company profile and that might be interested in the proposal of collaborative R&D project that you will be describing in this form. (Please use English language for filling in the document)

In the case that your company will establish a R&D project in collaboration with a Chinese company, you could benefit from the preferential financing given within the CHINEKA Program**.**

Company name: Rethink Medical S.L.

Number of employees: 4
Annual turnover: - (development phase)
Balance Total: 82.000 EUR
Year of latest financial report: 2019

Address: Calle Practicante Ignacio Rodríguez S/N Edificio Polivalente II del Campus Universitario de Tafira **City:** Las Palmas de Gran Canaria **Province:** Las Palmas **Postal Code:** 35017	**Telephone:** +34 669678449 / +34 646307 642 **Fax:** - **Email:** szilvia@rethinkmedical.es / mluque@rethinkmedical.es **WEB site:** https://www.rethinkmedical.es/

Contact: Szilvia Endrényi **Position: CEO** **Telephone:** +34 669678449 **Email:** szilvia@rethinkmedical.es	**Additional Contact:** Manual Luque **Position:** CIO **Telephone:** +34 646 307 642 **Email:** mluque@rethinkmedical.es

COLLABORATIVE R&D PROJECT PROPOSAL

(Describe as precisely as possible the technology cooperation proposal. Describe what you have to offer and what you expect from your potential partner) Include: Sector Group; Abstract of Project; Innovations Offered; and Current State of Development

Title	Urinary catheter validation		
Duration (YM- YM)	01/2021-12/2022		
Budget (1,000 Euro)	SPAIN	CHINA	TOTAL
	to be determined (min. 175.000 EUR)	to be determined by Chinese partner	
Technology Field (Click a box)	☐ Renewable energy ☐ Energy efficiency technology ☐ Smart Community technology ☐ Environment technology ☐ Robotics and Machinery systems technology ☐ Electronics, materials and nanotechnology ☐ Biotechnology **X** <u>Healthcare</u>		
Summary	Rethink Medical developed a novel urinary catheter, with integrated fluid controlling system, in order to increase work-efficiency at the hospital (adherence to guidelines and reduction of occupational risks), prevent infections and improve the quality of life of the patients, related to indwelling urinary catheters. The design of the product is frozen, functional prototypes validation is ongoing, with positive preliminary results. Apart from fundraising activities, we might be interested in contacting possible validation partners in China in the following areas: 1) biocompatibility testing Possible partner: any technological center or laboratory, certified to run biocompatibility testing of ClassIIa medical devices. The company should have experience with European notified bodies, as the study will be used for registration in Europe and the US. AND 2) clinical validation Possible partner: any hospital interested in PhIII comparative clinical trial in order to validate safety and efficiency. Possible endpoints to measure: - safety - infections - ease of usage among nurses and patients - quality of life improvement of patients Rethink Medical is responsible for manufacturing and assessment of the design of the clinical trial, but the partner has to assume full clinical-study management, including legal requirements, ethics committee, etc, assuming full responsibility in any sense.		

CHINESE PARTNERS

(When you know a potential Chinese company, write its name and contact details in this section.) Please, make a description of the desire type of Chinese Technology Partner.

Technological center or laboratory, certified to run biocompatibility testing of ClassIIa medical devices. The company should have experience with European notified bodies, as the study will be used for registration in Europe and the US.

AND

Hospital interested in PhIII comparative clinical trial in order to validate safety and efficiency. Rethink Medical is responsible for manufacturing and assessment of the design of the clinical trial, but the partner has to assume full clinical-study management, including legal requirements, ethics committee, etc, assuming full responsibility in any sense.

YOUR COMPANY DESCRIPTION

(Company Website, Research and development guidelines, strategic alliances, competitive position, etc)

(The minimum information to show the potential of your company)

Rethink Medical is a privately owned startup company, that based on nursing experience developed a new urinary catheter for chronic or acute patients.

The company is supported by important European institutions, such as EIT Health (through different specific programs), the European Commission (through SME Instrument program) and the CIMTI Healthcare acceleration program. It is also collaborating with European hospitals, such as the Karolinska Institute and SERMAS and counts with a diversified Advisory Board, with experience in clinical, commercial and regulatory issues.

Pre-clinical tests confirmed that the product has a high chance to disrupt the high volume (>200 million units in the EU and the US) and steadily growing (>5 % annual growth rate) urinary catheter market.

The company plans to launch the product in 2023, with relatively fast commercial scale-up - in case of successful validation -, as the project already raised the interest of several multinational distributors.

YOUR COMPANY PRODUCTS

(Technologies, applications, services, etc)

(The minimum information to show the potential of your company)

The company is involved in the development of an indwelling urinary catheter, to be clinically validated, registered and launched in the coming years.

The product is an indwelling urinary catheter, with fluid controlling system, in order to increase work-efficiency at the hospital, prevent infections and improve the quality of life of the patients. PRe-clinical validation results are very promising.

The product was designed by Rethink Medical´s engineers and the company is responsible for manufacturing. The product has a valid patent in the EU and the US and has an additional patent application filed.